Amundi
VRTX icon

Amundi’s Vertex Pharmaceuticals VRTX Stock Holding History

Amundi’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$768M Buy
1,546,509
+74,013
+5% +$32.8M 0.18% 92
2026
Q1 		$658M Buy
1,472,496
+168,335
+13% +$78.5M 0.18% 105
2025
Q4 		$591M Buy
1,304,161
+185,190
+17% +$79.8M 0.16% 133
2025
Q3 		$451M Sell
1,118,971
-14,255
-1% -$5.96M 0.14% 130
2025
Q2 		$518M Sell
1,133,226
-1,965,643
-63% -$906M 0.18% 107
2025
Q1 		$1.5B Sell
3,098,869
-182,336
-6% -$85M 0.55% 29
2024
Q4 		$1.35B Sell
3,281,205
-478,031
-13% -$222M 0.47% 37
2024
Q3 		$1.73B Buy
3,759,236
+255,177
+7% +$123M 0.64% 26
2024
Q2 		$1.65B Sell
3,504,059
-79,024
-2% -$34.3M 0.63% 23
2024
Q1 		$1.41B Buy
3,583,083
+864,966
+32% +$366M 0.61% 27
2023
Q4 		$1.14B Buy
2,718,117
+774,696
+40% +$286M 0.51% 32
2023
Q3 		$721M Buy
1,943,421
+297,580
+18% +$104M 0.35% 57
2023
Q2 		$572M Sell
1,645,841
-393,077
-19% -$132M 0.29% 79
2023
Q1 		$656M Sell
2,038,918
-91,279
-4% -$27.4M 0.35% 59
2022
Q4 		$623M Buy
2,130,197
+304,875
+17% +$92.9M 0.34% 68
2022
Q3 		$551M Buy
1,825,322
+893,935
+96% +$257M 0.33% 65
2022
Q2 		$267M Buy
931,387
+338,889
+57% +$90.7M 0.21% 122
2022
Q1 		$163M Sell
592,498
-231,256
-28% -$54.9M 0.11% 214
2021
Q4 		$187M Buy
823,754
+133,856
+19% +$26M 0.12% 201
2021
Q3 		$125M Buy
689,898
+16,172
+2% +$3.16M 0.09% 247
2021
Q2 		$136M Buy
+673,726
New +$141M 0.09% 219

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Amundi's VRTX Position: Q2 2026 in Review

Amundi increased its Vertex Pharmaceuticals (VRTX) stake by 5% in Q2 2026, buying an estimated $32.8M and bringing the position to 1,546,509 shares worth $768M. The position accounts for 0.18% of the portfolio, ranked #92.

Amundi first reported a position in VRTX in Q2 2021 and has held it in 21 quarters since. The position peaked at $1.73B in Q3 2024. 1,756 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Amundi held 1,546,509 shares of Vertex Pharmaceuticals worth $768M as of Q2 2026.
  • Amundi bought 74,013 Vertex Pharmaceuticals shares in Q2 2026, an estimated $32.8M.
  • Vertex Pharmaceuticals made up 0.18% of Amundi's portfolio in Q2 2026, its #92 holding.
  • Amundi first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Amundi's Vertex Pharmaceuticals position peaked at $1.73B in Q3 2024.
  • 1,756 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.